Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Omthera Pharmaceuticals

- PMLiVE

AZ gets EU green light for new antibiotic Zavicefta

EMA approves combination drug for treatment of multidrug resistant infections

- PMLiVE

CDC says no to AZ’s intranasal flu vaccine FluMist

US government data reports “poor” efficacy for the injected vaccine alternative

- PMLiVE

GSK’s triple COPD therapy tops Symbicort in phase III trial

Once-daily, single inhaler combination treatment showed “significant” improvement in lung function

- PMLiVE

Updated EMPA-REG data show Jardiance also protects kidney

Boehringer Ingelheim and Lilly’s drug is the first to show positive impact on kidney damage

- PMLiVE

AstraZeneca sells rights to seven anaesthetics in $770m deal

Ten-year agreement with Aspen continues the streamlining of its operations

- PMLiVE

AstraZeneca to develop Lynparza companion diagnostic

Will collaborate with Foundation Medicine on test for its ovarian cancer drug

AstraZeneca AZ

AZ sells Zurampic rights to Gruenenthal for $230m

Continues to sell off unwanted assets in order to focus resources and meet $45bn sales target

- PMLiVE

GSK brings forward triple COPD therapy filing in US

Intends to file the three-drug respiratory therapy by the end of 2016

National Institute for Health and Care Excellence NICE logo

NICE backs freer use of SGLT2 inhibitors for diabetes

Recommendation positions Invokana, Forxiga and Jardiance as first-line treatments

China drug medicine pharma prices

Prices of AZ and GSK drugs slashed in China

GSK says price reductions represent  “defining moment” in improving patient outcomes

AstraZeneca AZ global R&D corporate HQ

AZ gets orphan status for selumetinib in thyroid cancer

Drug already in phase III testing for KRAS-mutant advanced NSCLC

UK flag

UK biopharma says Brexit would be “bad for business”

Over 90 industry leaders sign letter supporting the Remain campaign

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links